Long-Term Protective Immune Response Elicited by Vaccination with an Expression Genomic Library of Toxoplasma gondii

ABSTRACT Immunization of BALB/c mice with an expression genomic library of Toxoplasma gondii induces a Th1-type immune response, with recognition of several T. gondii proteins (21 to 117 kDa) and long-term protective immunity against a lethal challenge. These results support further investigations to achieve a multicomponent anti-T. gondii DNA vaccine.

Download Full-text

Protective Immune Response in BALB/c Mice Induced by DNA Vaccine of the ROP8 gene of Toxoplasma gondii

American Journal of Tropical Medicine and Hygiene ◽

10.4269/ajtmh.12-0727 ◽

2013 ◽

Vol 88 (5) ◽

pp. 883-887 ◽

Cited By ~ 24

Author(s):

Sonaimuthu Parthasarathy ◽

Yee Ling Lau ◽

Kalyanasundaram Ramaswamy ◽

Mun Yik Fong

Keyword(s):

Immune Response ◽

Toxoplasma Gondii ◽

Dna Vaccine ◽

Protective Immune Response

Download Full-text

Protective immune response in BALB/c mice induced by a suicidal DNA vaccine of the MIC3 gene of Toxoplasma gondii

Veterinary Parasitology ◽

10.1016/j.vetpar.2009.06.012 ◽

2009 ◽

Vol 164 (2-4) ◽

pp. 134-140 ◽

Cited By ~ 29

Author(s):

Rui Fang ◽

Hao Nie ◽

Zhengsong Wang ◽

Pan Tu ◽

Danna Zhou ◽

...

Keyword(s):

Immune Response ◽

Toxoplasma Gondii ◽

Dna Vaccine ◽

Protective Immune Response ◽

Suicidal Dna Vaccine

Download Full-text

Protective immune response against Toxoplasma gondii elicited by a recombinant DNA vaccine with a novel genetic adjuvant

Vaccine ◽

10.1016/j.vaccine.2012.01.004 ◽

2012 ◽

Vol 30 (10) ◽

pp. 1800-1806 ◽

Cited By ~ 30

Author(s):

Huaiyu Zhou ◽

Juan Min ◽

Qunli Zhao ◽

Qinmin Gu ◽

Hua Cong ◽

...

Keyword(s):

Immune Response ◽

Toxoplasma Gondii ◽

Dna Vaccine ◽

Recombinant Dna ◽

Protective Immune Response

Download Full-text

Protective immune response in mice induced by a suicidal DNA vaccine encoding NTPase-II gene of Toxoplasma gondii

Acta Tropica ◽

10.1016/j.actatropica.2016.12.004 ◽

2017 ◽

Vol 166 ◽

pp. 336-342 ◽

Cited By ~ 8

Author(s):

Lina Zheng ◽

Yue Hu ◽

Qianqian Hua ◽

Fangjun Luo ◽

Guizhen Xie ◽

...

Keyword(s):

Immune Response ◽

Toxoplasma Gondii ◽

Dna Vaccine ◽

Protective Immune Response ◽

Suicidal Dna Vaccine

Download Full-text

A Novel Combined DNA Vaccine Encoding Toxoplasma gondii SAG1 and ROP18 Provokes Protective Immunity Against a Lethal Challenge in Mice

Acta Parasitologica ◽

10.1007/s11686-021-00415-2 ◽

2021 ◽

Author(s):

Lamei Wu ◽

Huijian Yang ◽

Jianglin Wang ◽

Xiuwen Yu ◽

Yanhong He ◽

...

Keyword(s):

Toxoplasma Gondii ◽

Dna Vaccine ◽

Protective Immunity ◽

Lethal Challenge

Download Full-text

Faculty Opinions recommendation of Astrocytes promote a protective immune response to brain Toxoplasma gondii infection via IL-33-ST2 signaling.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738912780.793588181 ◽

2021 ◽

Author(s):

George Yap ◽

Azadeh Nasuhidehnavi

Keyword(s):

Immune Response ◽

Toxoplasma Gondii ◽

Protective Immune Response ◽

Toxoplasma Gondii Infection

Download Full-text

Virus-Vectored Ebola Vaccines

Acta Naturae ◽

10.32607/20758251-2017-9-3-4-11 ◽

2017 ◽

Vol 9 (3) ◽

pp. 4-11 ◽

Cited By ~ 9

Author(s):

I. V. Dolzhikova ◽

E. A. Tokarskaya ◽

A. S. Dzharullaeva ◽

A. I. Tukhvatulin ◽

D. V. Shcheblyakov ◽

...

Keyword(s):

Clinical Trial ◽

Immune Response ◽

West Africa ◽

Protective Immunity ◽

Viral Vectors ◽

Ebola Virus ◽

Virus Disease ◽

Genetically Engineered ◽

Preclinical Trials

The Ebola virus disease (EVD) is one of the most dangerous infections affecting humans and animals. The first EVD outbreaks occurred in 1976 in Sudan and Zaire. Since then, more than 20 outbreaks have occurred; the largest of which (2014-2016) evolved into an epidemic in West Africa and claimed the lives of more than 11,000 people. Although vaccination is the most effective way to prevent epidemics, there was no licensed vaccine for EVD at the beginning of the latest outbreak. The development of the first vaccines for EVD started in 1980 and has come a long technological way, from inactivated to genetically engineered vaccines based on recombinant viral vectors. This review focuses on virus-vectored Ebola vaccines that have demonstrated the greatest efficacy in preclinical trials and are currently under different phases of clinical trial. Particular attention is paid to the mechanisms of immune response development, which are important for protection from EVD, and the key vaccine parameters necessary for inducing long-term protective immunity against EVD.

Download Full-text